oleanolic acid has been researched along with Chronic Kidney Diseases in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 43 (91.49) | 24.3611 |
| 2020's | 4 (8.51) | 2.80 |
| Authors | Studies |
|---|---|
| Iwano, M; Kasuno, K; Yodoi, J | 1 |
| Fukiya, H; Horizono, J; Kai, H; Kamura, M; Kaseda, S; Koyama, Y; Kuwazuru, J; Nara, F; Niinou, S; Nishiyama, H; Ogi, S; Onuma, K; Sannomiya, Y; Sasaki, R; Shuto, T; Suico, MA; Sunamoto, H | 1 |
| Avula, UMR; Harris, L; Hassanein, M | 1 |
| Ito, M; Nangaku, M | 1 |
| Gamede, M; Khathi, A; Mabuza, L; Ngubane, P | 1 |
| Nezu, M; Suzuki, N; Yamamoto, M | 1 |
| Toto, RD | 1 |
| Baigent, C; Lennon, R | 1 |
| An, HJ; Gu, H; Gwon, MG; Jang, KM; Kim, JY; Park, B; Park, JH; Park, KK | 1 |
| Appel, GB; Block, GA; Chertow, GM; Chin, MP; Coyne, DW; Goldsberry, A; Kalantar-Zadeh, K; Meyer, CJ; Molitch, ME; Pergola, PE; Raskin, P; Rossing, P; Silva, AL; Spinowitz, B; Sprague, SM | 1 |
| Chin, MP; Goldsberry, A; McCullough, PA; Meyer, CJ; O'Grady, M; Pergola, PE; Rizk, DV; Silva, AL; Toto, R; Warnock, DG | 1 |
| Solomon, R | 1 |
| Kalantar-Zadeh, K; Tayek, JA | 1 |
| Agarwal, R; Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; de Zeeuw, D; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Pergola, PE; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Warnock, DG; Wittes, J | 1 |
| Fu, L; Gribble, GW | 1 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Krauth, M; Lambers Heerspink, HJ; Linde, P; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
| Aminzadeh, MA; Khazaeli, M; Meyer, CJ; Reisman, SA; Vaziri, ND; Yuan, J | 1 |
| Himmelfarb, J; Tuttle, KR | 2 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Houser, M; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
| Aminzadeh, MA; Farzaneh, SH; Khazaeli, M; Meyer, CJ; Reisman, SA; Shelkovnikov, S; Vaziri, ND | 1 |
| Attley, J; Cuzzocrea, S; Esposito, E; Impellizzeri, D | 1 |
| Chertow, GM; de Zeeuw, D | 1 |
| Chartoumpekis, DV; Sykiotis, GP | 1 |
| Kovács, T; Molnár, GA; Wittmann, I | 1 |
| Ellison, DH | 1 |
| Bakris, GL; Chin, MP; Linde, PG; McCullough, PA; Meyer, CJ; O'Grady, M; Packham, D; Reisman, SA; Vaziri, ND; Ward, KW; Warnock, DG | 1 |
| Van Biesen, W; Van Laecke, S; Vanholder, R | 1 |
| de Zeeuw, D; Meyer, C | 1 |
| Bakris, GL; Chertow, GM; Chin, MP; de Zeeuw, D; Goldsberry, A; Linde, PG; McCullough, PA; McMurray, JJ; Meyer, CJ; Wittes, J; Wrolstad, D | 1 |
| He, ZX; Wang, YY; Yang, YX; Zhe, H; Zhou, SF | 1 |
| Chan, JY; Khazaeli, M; Lau, WL; Liu, SM; Ni, Z; Pahlevan, S; Vaziri, ND; Yuan, J | 1 |
| Chin, MP; Meyer, CJ | 1 |
| Camer, D; Huang, XF | 1 |
| Farzaneh, SH; Khazaeli, M; Liu, S; Nazertehrani, S; Vaziri, ND; Zhao, YY | 1 |
| Breyer, MD; Susztak, K | 1 |
| Audhya, P; Christ-Schmidt, H; Grossman, EB; Huff, JW; Krauth, M; Meyer, CJ; Pergola, PE; Raskin, P; Ruiz, S; Toto, RD; Warnock, DG; Wittes, J | 1 |
| Van Laecke, S; Vanholder, R | 1 |
| Bittenbring, JT; Fliser, D; Rogacev, KS | 1 |
| Levey, AS; Sarnak, MJ; Upadhyay, A | 1 |
| Forman, JP; McMahon, GM | 1 |
| Abramowitz, MK; Bauer, C; Hostetter, TH; Melamed, ML; Turner, JM | 1 |
| Boffa, JJ; Chatziantoniou, C; Dussaule, JC; Ronco, P | 1 |
| Merk, D; Schubert-Zsilavecz, M | 1 |
| Zhang, DD | 1 |
| Pergola, PE; Ruiz, S; Vaziri, ND; Zager, RA | 1 |
| Saito, H | 1 |
8 review(s) available for oleanolic acid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Urinary Thioredoxin as a Biomarker of Renal Redox Dysregulation and a Companion Diagnostic to Identify Responders to Redox-Modulating Therapeutics.
Topics: Acute Kidney Injury; Biomarkers; Female; Humans; Male; Oleanolic Acid; Oxidation-Reduction; Renal Insufficiency, Chronic; Thioredoxins | 2022 |
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Topics: Acute Kidney Injury; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Glomerular Filtration Rate; Humans; Kelch-Like ECH-Associated Protein 1; Kidney Tubules; Mice; Molecular Targeted Therapy; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Proteasome Endopeptidase Complex; Proteolysis; Reactive Oxygen Species; Renal Insufficiency, Chronic; Signal Transduction; Ubiquitination | 2017 |
Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Topics: Amides; Animals; Anti-Inflammatory Agents; Endocannabinoids; Ethanolamines; Humans; Oleanolic Acid; Palmitic Acids; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Topics: Animals; Humans; Hypertension, Pulmonary; Inflammation; Neoplasms; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Treatment of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mellitus, Type 2; Disease Progression; Endothelin-1; Humans; Hypertension; Kidney Failure, Chronic; Oleanolic Acid; Pyridones; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Anti-Infective Agents; Antioxidants; Disease Progression; Humans; Inflammation; Kidney; Kidney Failure, Chronic; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2013 |
Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases.
Topics: Acute Kidney Injury; Animals; Antioxidants; Chronic Disease; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Reactive Oxygen Species; Renal Insufficiency; Renal Insufficiency, Chronic; Signal Transduction | 2013 |
8 trial(s) available for oleanolic acid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Oleanolic Acid; Renal Insufficiency, Chronic; Waist Circumference | 2018 |
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Glomerular Filtration Rate; Humans; Magnesium; Male; Middle Aged; Oleanolic Acid; Renal Insufficiency, Chronic | 2019 |
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
Topics: Anti-Inflammatory Agents; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Early Termination of Clinical Trials; Glomerular Filtration Rate; Humans; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Oleanolic Acid; Prognosis; Renal Insufficiency, Chronic; Young Adult | 2013 |
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; NF-E2-Related Factor 2; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Failure; Weight Loss | 2013 |
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Topics: Animals; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Heart Failure; Humans; Macaca fascicularis; Male; Oleanolic Acid; Rats; Renal Insufficiency, Chronic; Sodium; Urine; Water-Electrolyte Imbalance | 2014 |
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Topics: Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oleanolic Acid; Patient Safety; Predictive Value of Tests; Reference Values; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome | 2014 |
Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oleanolic Acid; Renal Insufficiency, Chronic; Spasm | 2011 |
31 other study(ies) available for oleanolic acid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
Topics: Animals; Disease Models, Animal; Kelch-Like ECH-Associated Protein 1; Mice; Nephritis, Hereditary; NF-E2-Related Factor 2; Oleanolic Acid; Phenotype; Renal Insufficiency, Chronic | 2022 |
Bardoxolone for CKD: The Paradox of Confusion and Dogma.
Topics: Humans; Oleanolic Acid; Renal Insufficiency, Chronic | 2022 |
Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Humans; Oleanolic Acid; Renal Insufficiency, Chronic; Retrospective Studies | 2019 |
Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model.
Topics: Animals; Biomarkers; Diabetic Nephropathies; Diet; Diet, High-Fat; Dietary Carbohydrates; Glomerular Filtration Rate; Hypoglycemic Agents; Kidney Function Tests; Male; Metformin; Oleanolic Acid; Oxidative Stress; Prediabetic State; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Syzygium | 2021 |
Bardoxolone-the Phoenix?
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Heart Failure; Humans; Nephritis, Hereditary; Oleanolic Acid; Renal Insufficiency, Chronic | 2018 |
Should We Increase GFR with Bardoxolone in Alport Syndrome?
Topics: Albuminuria; Anti-Inflammatory Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Heart Failure; Humans; Nephritis, Hereditary; Oleanolic Acid; Renal Insufficiency, Chronic | 2018 |
Pomolic Acid Ameliorates Fibroblast Activation and Renal Interstitial Fibrosis through Inhibition of SMAD-STAT Signaling Pathways.
Topics: Animals; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Gene Expression Regulation; Male; Mice; Oleanolic Acid; Renal Insufficiency, Chronic; Signal Transduction; Smad Proteins; STAT Transcription Factors; Transforming Growth Factor beta1 | 2018 |
New Approach to Slowing the Progression of Chronic Kidney Disease.
Topics: Disease Progression; Healthy Volunteers; Humans; Oleanolic Acid; Renal Insufficiency, Chronic | 2019 |
The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.
Topics: Anti-Inflammatory Agents; Diabetic Nephropathies; Early Termination of Clinical Trials; Humans; Oleanolic Acid; Proteinuria; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Spasm; Weight Loss | 2013 |
Efficient and scalable synthesis of bardoxolone methyl (cddo-methyl ester).
Topics: Anti-Inflammatory Agents; Chromatography; Diabetes Mellitus, Type 2; Esters; Humans; Molecular Structure; Oleanolic Acid; Renal Insufficiency, Chronic | 2013 |
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.
Topics: Animals; Blotting, Western; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Kidney; Male; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; RNA, Messenger; Signal Transduction; Smad7 Protein; Transforming Growth Factor beta | 2014 |
New therapies for diabetic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2013 |
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Topics: Animals; Aorta; Endothelial Cells; Gene Expression Regulation; Inflammation; Male; Nephrectomy; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic | 2013 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
The paradox of bardoxolone methyl: a call for every witness on the stand?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
The paradox created by commenting on large clinical trial results.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Case-Control Studies; Colitis; Colon; Disease Models, Animal; Inflammation Mediators; Intestinal Mucosa; Male; Nephrectomy; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Tight Junction Proteins; Tight Junctions; Uremia | 2015 |
Reply: To PMID 25307295.
Topics: Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Heart Failure; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Is B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl?
Topics: Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Heart Failure; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
Topics: Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Kidney; Male; NF-E2-Related Factor 2; Oleanolic Acid; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction | 2015 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2011 |
[Chronic kidney disease, new therapeutic approaches].
Topics: Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Oleanolic Acid; Prognosis; Protein Kinase Inhibitors; Renal Insufficiency, Chronic; Treatment Outcome | 2012 |
New hope or drawbacks: will chronic kidney disease be treatable with small molecules in the near future?
Topics: Anti-Inflammatory Agents; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Kidney; NF-E2-Related Factor 2; Oleanolic Acid; Renal Insufficiency, Chronic | 2012 |
Bardoxolone brings Nrf2-based therapies to light.
Topics: Clinical Trials, Phase III as Topic; Humans; NF-E2-Related Factor 2; Oleanolic Acid; Renal Insufficiency, Chronic | 2013 |